ESR2 and mantle cell lymphoma: Notably, the ibrutinib-resistant Granta-519, Z-138, and Maver-1 cells [19] responded to the treatment with an ESR2-selective agonist, similar to the ibrutinib-sensitive Mino and JeKo-1 MCL tumors, as demonstrated in this report.